'Hcv genotype' diaporamas de présentation

Telaprevir ( Incivek )

Telaprevir ( Incivek ). Prepared by: David Spach, MD & H. Nina Kim, MD Last Updated : February 3, 2014. Telaprevir ( Incivek ). Background and Dosing. Telaprevir ( Incivek ). Approval : FDA Approved May 23, 2011

1.06k views • 87 slides

MEDICAL GRANDROUNDS

659 views • 58 slides

Teerha Piratvisuth MD. Prince of Songkla University

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy. Teerha Piratvisuth MD. Prince of Songkla University. Treatment of chronic hepatitis C and response rates. 41%. NGI <100 copies/ml. 33%. 16%. Sustained Virologic Response.

710 views • 53 slides

Treatment of Chronic HCV Genotype 3

Treatment of Chronic HCV Genotype 3. Robe rt G. Gish MD Staff Physician, Stanford University Medical Center Senior Medical Director, St Josephs Hospital and Medical Center, Liver Program, Phoenix , Arizona Clinical Professor of Medicine, University of Nevada, Las Vegas

595 views • 49 slides

HCV/HIV Co-infection: Understanding our Challenges and Opportunities

HCV/HIV Co-infection: Understanding our Challenges and Opportunities. Kay Schwebke, MD, MPH Infectious Diseases HCMC HIV/AIDS Program. Case Presentation. 35 year old woman, HIV/HCV co-infected History of depression and polysubstance use disorder with ongoing alcohol use CD4 = 199

662 views • 47 slides

HCV/HIV Co-infection: Understanding our Challenges and Opportunities

HCV/HIV Co-infection: Understanding our Challenges and Opportunities. Kay Schwebke, MD, MPH Infectious Diseases HCMC HIV/AIDS Program. Case Presentation. 35 year old woman, HIV/HCV co-infected History of depression and polysubstance use disorder with ongoing alcohol use CD4 = 199

553 views • 47 slides

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness. Prepared for: Agency for Healthcare Research and Quality (AHRQ) www.ahrq.gov. Outline of Material. Introduction to hepatitis C virus (HCV) infection and the various therapies available for its treatment

503 views • 34 slides

Infective Hepatitis: hepatitis B & C

Infective Hepatitis: hepatitis B & C. Hepatitis. Hepatitis. Liver is a vital organ of the body. Functions include: Processing food for energy conversion Neutralise toxins and other drugs Store iron and important vitamins Process hormones Fight infections

932 views • 33 slides

New drugs for HCV treatment in solid organ transplantation Xavier Forns Liver Unit

457 views • 30 slides

Hepatitis C Primer for HIV Care Providers

Hepatitis C Primer for HIV Care Providers. Adeel A. Butt, MD Assistant Professor of Medicine Division of Infectious Diseases University of Pittsburgh Director, Pittsburgh VAMC ID-HIV Clinics Center for Health Equity Research and Promotion. Member of Academic Research Council

330 views • 26 slides

HIV/HCV co-infection in Taiwan

HIV/HCV co-infection in Taiwan. Nai-Ying Ko RN. PhD., Hsin-Chun Lee MD, Shainn-Wei Wang PhD., Wen-Chien Ko MD, National Cheng Kung University & Hospital Taiwan. Topics. Molecular epidemiology of HIV/HCV coinfection in Taiwan

608 views • 24 slides

Treating coinfection in Asia: Challenges and unmet needs

Treating coinfection in Asia: Challenges and unmet needs. Anchalee Avihingsanon, MD, PhD HIV-NAT, Thai Red Cross AIDS Research Centre, Thailand July2, 2013. HIV/HCV coinfection: Public Health Challenges in Asia . prevalence, HCV genotype distribution and disease progression

360 views • 23 slides

Cirrhosis

Cirrhosis. Dr. Meg- angela Christi M. Amores. Cirrhosis. a histopathologically defined condition pathologic features consist of the development of fibrosis to the point that there is architectural distortion with the formation of regenerative nodules Decreased mass and function .

446 views • 19 slides

Sofosbuvir-Velpatasvir in HCV Genotype 1, 2, 4, 5, or 6 ASTRAL-1

196 views • 11 slides

Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON

Phase 3. Interferon Intolerant, Unwilling, or Ineligible. Sofosbuvir in HCV Genotype 2, 3 (PEG not an Option) POSITRON. *Note: Published in tandem with FUSION Trial (GT 2,3 and prior failure with PEG). Jacobson I, et al. N Engl J Med. 2013;368:1867-77.

220 views • 11 slides

Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-1

267 views • 8 slides

Boceprevir with PEG + RBV in Genotype 1 SPRINT -1

166 views • 7 slides

Treatment of Chronic HCV Genotype 2 thru 6

323 views • 6 slides

180 views • 6 slides

Predictors of HCV treatment post Liver biopsy

Low HCV Treatment Rates after a Liver Biopsy O.M Adeyemi , B. Attar, G. Huhn , D. Wolen , M. Gallagher, R. Goldberg CORE Center, Stroger Hosp. of Cook County, Chicago, IL and Rush Medical College,Chicago , IL. 48 th ICAAC/IDSA meeting, Washington, DC October 25-28, 2008. V-1637.

203 views • 1 slides